Cargando…

Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States

BACKGROUND: Lipoprotein(a) (Lp(a)) is an inherited, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To assess the burden of elevated Lp(a) for patients with ASCVD in a real-world setting in the United States. METHODS: This retrospective cohort study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fonseca, Ana F, Byrne, Hannah, Laguna, Andres, Itani, Taha, Studer, Rachel, Heo, Jihaeng, Dillon, Allison, Ferber, Philippe, Costa-Scharplatz, Madlaina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387958/ https://www.ncbi.nlm.nih.gov/pubmed/37121256 http://dx.doi.org/10.18553/jmcp.2023.29.5.519

Ejemplares similares

Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis
por: Orfanos, Panagiotis, et al.
Publicado: (2023)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care
por: Korolainen, Minna A., et al.
Publicado: (2019)

Economic burden of COPD in a Swedish cohort: the ARCTIC study
por: Lisspers, Karin, et al.
Publicado: (2018)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study
por: Lindmark, Krister, et al.
Publicado: (2021)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review
por: Puhan, Milo A, et al.
Publicado: (2005)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023)

Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study
por: Davidge, Jason, et al.
Publicado: (2022)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? – A systematic review
por: Scharplatz, Madlaina, et al.
Publicado: (2005)

Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden
por: Boman, Kurt, et al.
Publicado: (2021)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
por: Lawler, Patrick R., et al.
Publicado: (2017)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Correction: Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Publicado: (2022)

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression
por: Kaiser, Yannick, et al.
Publicado: (2022)

Plasma lipoprotein (a) and tissue plasminogen activator are associated with increased risk of atherosclerotic cardiovascular disease
por: Mayyas, Fadia, et al.
Publicado: (2022)

The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients
por: Wang, Xiaoyu, et al.
Publicado: (2023)

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases
por: Ezhov, Marat V., et al.
Publicado: (2021)

Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease
por: Niccoli, Giampaolo, et al.
Publicado: (2016)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients
por: Rafieian-Kopaei, Mahmoud, et al.
Publicado: (2013)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease
por: Trinder, Mark, et al.
Publicado: (2020)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review
por: Sascău, Radu, et al.
Publicado: (2021)

Digital Health Solutions to Reduce the Burden of Atherosclerotic Cardiovascular Disease Proposed by the CARRIER Consortium
por: Scheenstra, Bart, et al.
Publicado: (2022)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events
por: Mani, Venkatesh, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_a6bnf4ut5olvsdp77u2hea1nb1